Forecasted demand for Current and New ARV medicines in low and middle income countries, 2016-2026

Aastha Gupta
on behalf of Medicines Patent Pool and World Health Organization
New drugs in the pipeline – some approved, some expected soon

Licences for these drugs will stimulate generic manufacturing, appropriate formulations such as FDCs, increased availability and affordable prices

However, for full and early benefit, all public health actors need to be informed, prepared and aligned

- Generics manufacturers need to understand volumes required and when
- Policy makers need to understand when generics would be available and in what formulations
- Procurement agents need to understand pricing and timing
- SRA and country level registration need to be expedited to accelerate access in the countries

Forecasts are a key element to start and prioritise the process of putting a new drug on the market as well as answering some of the questions above
Key Variables

- WHO guidelines: what & when?
- Availability of FDCs
- National guidelines
- Data in special populations (TB, pregnancy)
- Launch price; price erosion
- Date of generic availability
UPTAKE CURVES: EXAMPLE OF DTG
**Uptake curves**

- Baseline = historical use trend for TDF per GPRM, linearized
- Other uptake curves are based on the above
- Each new product follows one of these curves based on the scenario and based on each product
- At different times, one product may follow different curves, taking into account higher or lower usage of drug with each year (example in next slide)
Example of Uptake curve used for DTG in first line treatment

- Initial uptake is conservative = 50% of baseline
- DTG recommended as alternate use in first line (as per WHO Guidelines 2015)
- FDCs not available initially
- Country registrations and uptake is limited
- Price comparable with EFV

The model uses different uptake curves for DTG for 1st line ART post its introduction in 2017 (likely scenario)
Example of Uptake curve used for DTG in first line treatment

- Uptake from Year 3 = 125% baseline
- Study results in special populations are available and positive
- Generic FDCs available
- WHO guidelines shift the product to a preferred treatment in first line
- More national approvals
- Price of single agent falls
Example of Uptake curve used for DTG in first line treatment

Uptake from Year 6 = 150% baseline
- Price drop of generic FDCs
- More national approvals
- Widespread country level use
FORECAST FOR ADULT / ADOLESCENT USE
Assumptions on Likely Scenario

Date of Introduction
- DTG 50mg: Q4-2017
- DTG FDCs: Q3-2018
- TAF FDCs: Q1-2019

Price Differential
- Launch Price:
  - DTG & TAF priced at par with EFV & TDF respectively
- Future pricing basis historical erosion trends

Clinical Assumptions
- Positive study results for DTG & TAF in TB co-infection and pregnant women
  - Including potential drug-drug interaction of TAF with RIF
- WHO Guidelines recommend new ARVs: first as alternate and then as preferred

Country Level Uptake
- New products come on National Guidelines within one year from WHO recommendation
- Use starts shortly thereafter
Millions of Adults Treated in WHO/MPP* forecasts

*WHO/MPP assumes total PLHIV treated per UNAIDS fast track report
Percent of adults on **first line** treatment taking TAF, TDF and AZT

- TDF is the clear market leader currently and continues to be so in the near future
- At launch, TAF price is assumed to be at par with TDF, however, our model assumes a conservative uptake due to lack of clinical data and its potential interaction with rifampicin
  - The TAF uptake picks up in later years, once such information is available, reaching 27% patients in first-line
- We assume AZT usage follows WHO Guidelines and continues to fall to negligible share by 2019 and tenofovir in both its forms takes over the market for first line nucleosides
With the WHO Guidelines recommendation of EFV as a preferred regimen, the market share of NVP declines to reach zero by 2020.

EFV gains 100% of the market share from NVP decline till the introduction of DTG.

DTG, when introduced, is assumed to be priced at par with EFV.

- We assume DTG rapidly takes market share of first-line treatment from both NVP as well as EFV.
- The uptake is slower in the initial years due to non-availability of FDCs, however, from 2019 onwards, the uptake increases substantially, reaching 63% of total first-line market.
Percent of adults on **second line** treatment taking DTG, TAF, TDF and AZT

- We assume a higher uptake of AZT in second-line treatment, since most patients are assumed to be using tenofovir in first line
- We also assume that TAF would be taking some market share from TDF, but the total market of tenofovir is small
- DTG
  - Is not recommended in the current WHO guidelines in second line
  - However, the assumption for uptake is that patients who have not used DTG in first line would be able to do so in second line
  - The uptake is much more conservative than for first-line use, and reaches 33% patients by 2026
Percent of adults on second line treatment taking LPV, ATV and DRV

- ATV is assumed to increase its market share in second-line due to
  - Availability of multiple generics
  - Price erosion due to competition
  - Once daily regimen
- LPV market share will thus decline in the coming years, with ATV eating into its market
- The role of DRV is very limited, as its price as well as large pill size are handicaps compared to ATV
Salvage treatment in adults

The main change between 2015 and 2026 in salvage treatment is the number of patients, which increase from 26,000 currently to 0.6 million in 2026.

The mix of ARVs used does not change much except DTG will take market share from RAL, which is the other integrase inhibitor.
ARV use in 2020 - Million People by Active Ingredient

Number of PLHIV (mn)

- 0.1 TAF
- 20.6 TDF
- 2.4 AZT
- 16.3 EFV
- 1.3 LPV
- 1.4 ATV
- 0.2 DRV
- 4.9 DTG
- 0.2 RAL

API for all formulations included
ARV use in 2026 - Million People by Active Ingredient

API for all formulations included
FORECAST FOR PAEDIATRIC USE
High Level Assumptions

• Date of introduction in market (either originator or generic):
  • DTG 50mg and FDCs: 2018
  • TAF FDCs: 2020

• Price:
  • At launch, DTG & TAF priced at par with EFV & TDF respectively
  • Future pricing based on historical price erosion trends

• Positive study results for DTG and TAF in children

• WHO guidelines recommend new products first as alternate and then as preferred regimens

• New products placed on national guidelines within one year from WHO guidelines
Millions of Children Treated in WHO/MPP* forecasts

*WHO/MPP assumes total PLHIV treated per UNAIDS fast track report
Abacavir is clearly the preferred NRTI for use in children, the increasing use of which is attributed to its being the preferred backbone with EFV as well as LPV.

- This could be true for DTG as well particularly if an FDC of ABC/3TC/DTG becomes available.

- Use of AZT declines as a result.

- We do not project uptake of TDF due to toxicity concerns and lack of appropriate formulations.

- There may be low use of TAF in the early years pending clinical validation.
Percentage of children on **first line** treatment using NNRTI, PI and INSTIs

- Since NVP is an alternate as per current WHO Guidelines, it is estimated to decline to zero by 2021.
- EFV being the preferred drug in first line for >3y, increases in the first few years, later declining to be replaced by DTG in children >3y from 2018.
- LPV, currently preferred for <3y, will also be replaced by DTG from 2020 onward.
- DTG
  - Will start being used in children 6-12y once generics are made available by 2018.
  - Will replace EFV in children >3y starting 2018, with availability of generics and
  - Will replace LPV in children <3y once data is available by 2020.
Percentage of children on **second line** treatment using NRTIs

- In second-line treatment, we assume an increased use of AZT, since most children would be using ABC in first line
- However, once ABC is available as an FDC with DTG, there will be a stability in its market share as is seen from 2020 onwards
- For TDF, we already see it being used in 27% patients in the last ARV Use Survey. This trend would be likely to continue, though at a stable rate
  - We assume a very limited role of TAF in second line for children due to non availability of data
Percentage of children on **second line treatment using NNRTI, PI and INSTI**

- Limited use of EFV, which is assumed to decline to zero by 2020
- All children failing NRTIs in first line would move to PI in second line. We have assumed most of these children would move to LPV and some to ATV
- Children failing LPV in first line would move mainly to RAL, but those which are now >3y could also move to DTG
- **One thing to note here is that as in case of WHO guidelines for adults, we assume DTG would not be recommended in 2nd line for children. However, in the future some patients failing LPV when older than 3 years may move to DTG instead of RAL**
ARV use in 2020 and 2025 - Million Children by Active Ingredient

![Graph showing ARV use in 2020 and 2025 by active ingredient.](image)

API for all formulations included.
Conclusion

- Our forecasts include a mix of judgement and data
- New ARVs represent potential business opportunities for manufacturers
- Meanwhile, manufacture of existing products such as TDF and EFV would need to be ramped up to meet the growing demand due to higher number of patients forecasted to be on treatment
Acknowledgements

▪ Marco Vitoria, World Health Organization
▪ Martina Penazzato, World Health Organization
▪ Vincent Habiyambere, World Health Organization
▪ Boniface Dongmo, World Health Organization
▪ Sandeep Juneja, Medicines Patent Pool
▪ Peter Ghys, UNAIDS
▪ John Stover, Avenir Health
Thank You

Aastha Gupta

agupta@medicinespatentpool.org